Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1943 1
1944 1
1953 3
1954 1
1955 1
1956 1
1957 2
1959 2
1960 2
1963 2
1964 2
1965 1
1966 2
1967 5
1968 2
1969 6
1970 3
1971 1
1972 2
1973 6
1974 3
1975 12
1976 15
1977 15
1978 11
1979 18
1980 28
1981 20
1982 29
1983 33
1984 44
1985 37
1986 43
1987 54
1988 63
1989 75
1990 70
1991 81
1992 94
1993 92
1994 84
1995 107
1996 107
1997 116
1998 119
1999 104
2000 168
2001 191
2002 173
2003 179
2004 210
2005 210
2006 250
2007 225
2008 260
2009 280
2010 321
2011 367
2012 377
2013 403
2014 425
2015 502
2016 481
2017 504
2018 517
2019 513
2020 547
2021 583
2022 522
2023 487
2024 210

Text availability

Article attribute

Article type

Publication date

Search Results

9,417 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for martin vivo did
Search for Martin Vivodík instead (1 results)
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J, Ye X, Rousseau E, Januario T, Hamman BD, Rose CM, Cheung TK, Hinkle T, Soto L, Quinn C, Harbin A, Bortolon E, Chen X, Haskell R, Lin E, Yu SF, Del Rosario G, Chan E, Dunlap D, Koeppen H, Martin S, Merchant M, Grimmer M, Broccatelli F, Wang J, Pizzano J, Dragovich PS, Berlin M, Yauch RL. Cantley J, et al. Nat Commun. 2022 Nov 10;13(1):6814. doi: 10.1038/s41467-022-34562-5. Nat Commun. 2022. PMID: 36357397 Free PMC article.
Selective SMARCA2 degradation is achieved in the absence of selective SMARCA2/4 PROTAC binding and translates to potent in vitro growth inhibition and in vivo efficacy in SMARCA4 mutant models, compared to wild type models. ...Our study thus highlights the ability to trans …
Selective SMARCA2 degradation is achieved in the absence of selective SMARCA2/4 PROTAC binding and translates to potent in vitro growth inhi …
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
Ganapathy T, Radhakrishnan R, Sakshi S, Martin S. Ganapathy T, et al. Cancer Immunol Immunother. 2023 Feb;72(2):277-286. doi: 10.1007/s00262-022-03260-y. Epub 2022 Aug 12. Cancer Immunol Immunother. 2023. PMID: 35960333 Free PMC article. Review.
Indeed, CD19 gammadelta CAR T cell therapy to treat advanced lymphoma reached a milestone with the fast track status by FDA. However, reduced tumor-toxicity, homing, in vivo persistence and heterogeneity limits the translation of this therapy. ...
Indeed, CD19 gammadelta CAR T cell therapy to treat advanced lymphoma reached a milestone with the fast track status by FDA. However, reduce …
Contact Hypersensitivity.
Gaspari AA, Katz SI, Martin SF. Gaspari AA, et al. Curr Protoc Immunol. 2016 Apr 1;113:4.2.1-4.2.7. doi: 10.1002/0471142735.im0402s113. Curr Protoc Immunol. 2016. PMID: 27038464
Contact hypersensitivity (CHS) is a simple in vivo assay of cell-mediated immune function in which exposure of epidermal and dermal cells to exogenous haptens results in a delayed-type hypersensitivity (DTH) reaction that can be measured and quantified. ...
Contact hypersensitivity (CHS) is a simple in vivo assay of cell-mediated immune function in which exposure of epidermal and dermal c …
Anticancer Potential of Lichens' Secondary Metabolites.
Solárová Z, Liskova A, Samec M, Kubatka P, Büsselberg D, Solár P. Solárová Z, et al. Biomolecules. 2020 Jan 5;10(1):87. doi: 10.3390/biom10010087. Biomolecules. 2020. PMID: 31948092 Free PMC article. Review.
Although no clinical study has been conducted yet, there are number of in vitro and in vivo studies demonstrating anticancer effects of lichen metabolites. ...
Although no clinical study has been conducted yet, there are number of in vitro and in vivo studies demonstrating anticancer effects …
The Mechanical Microenvironment in Breast Cancer.
Pratt SJP, Lee RM, Martin SS. Pratt SJP, et al. Cancers (Basel). 2020 Jun 3;12(6):1452. doi: 10.3390/cancers12061452. Cancers (Basel). 2020. PMID: 32503141 Free PMC article. Review.
While mechanical stress and their resulting cellular responses occur in normal physiologic contexts, there are a variety of cancer-associated physical cues present in the tumor microenvironment that are pathological in breast cancer. Mechanistic in vitro data and in vivo e …
While mechanical stress and their resulting cellular responses occur in normal physiologic contexts, there are a variety of cancer-associate …
Fluorescence lifetime imaging ophthalmoscopy.
Dysli C, Wolf S, Berezin MY, Sauer L, Hammer M, Zinkernagel MS. Dysli C, et al. Prog Retin Eye Res. 2017 Sep;60:120-143. doi: 10.1016/j.preteyeres.2017.06.005. Epub 2017 Jun 30. Prog Retin Eye Res. 2017. PMID: 28673870 Free PMC article. Review.
Fluorescence lifetime imaging ophthalmoscopy (FLIO) is an emerging imaging modality for in vivo measurement of lifetimes of endogenous retinal fluorophores. ...
Fluorescence lifetime imaging ophthalmoscopy (FLIO) is an emerging imaging modality for in vivo measurement of lifetimes of endogenou …
Requirements for Animal Experiments: Problems and Challenges.
Fontana F, Figueiredo P, Martins JP, Santos HA. Fontana F, et al. Small. 2021 Apr;17(15):e2004182. doi: 10.1002/smll.202004182. Epub 2020 Oct 6. Small. 2021. PMID: 33025748 Review.
In vivo models remain a principle screening tool in the drug discovery pipeline. ...
In vivo models remain a principle screening tool in the drug discovery pipeline. ...
Introducing In Vivo.
Bellon R, Martin JD. Bellon R, et al. Endeavour. 2016 Sep;40(3):139-140. doi: 10.1016/j.endeavour.2016.09.001. Endeavour. 2016. PMID: 27692088 No abstract available.
Therapeutics administered during ex vivo liver machine perfusion: An overview.
Buchwald JE, Xu J, Bozorgzadeh A, Martins PN. Buchwald JE, et al. World J Transplant. 2020 Jan 18;10(1):1-14. doi: 10.5500/wjt.v10.i1.1. World J Transplant. 2020. PMID: 32110510 Free PMC article. Review.
In this review, we explore the current basic science research investigating therapeutics administered during ex vivo liver machine perfusion aimed at mitigating the effects of IRI in the liver transplantation process. These various categories of therapeutics are utilized d …
In this review, we explore the current basic science research investigating therapeutics administered during ex vivo liver machine pe …
9,417 results